Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 July 2007, Vol. 110, No. 1, pp. 6-7.

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mapara, M. Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mapara, M. Y.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

InsideBlood

IMMUNOBIOLOGY

Comment on Svegliati et al, page 237

Stimulating results with stimulatory antibodies

Markus Y. Mapara

UNIVERSITY OF PITTSBURGH CANCER INSTITUTE

In this issue of Blood, Svegliati and colleagues provide new insights into the mechanisms of chronic GVHD development by demonstrating the presence and functional activity of stimulatory anti–PDGF-R autoantibodies in patients with extensive chronic GVHD.

Graft-versus-host disease (GVHD) is one of the major causes of morbidity and mortality in allogeneic hematopoietic stem cell transplantation. In acute GVHD, tremendous progress has been made in recent years with a better understanding of the underlying pathophysiologic events. In contrast, the pathogenesis of chronic GVHD (cGVHD) is still a largely unknown territory with more questions than answers regarding the underlying mechanisms leading to this very complex and clinically challenging disease. The study by Svegliati and colleagues in this issue of Blood provides interesting new insights into the mechanistic aspects of cGVHD development bearing potential therapeutic implications. Based on the clinical presentation of cGVHD with sclerodermatous and lichenoid lesions, Sjogren-like symptoms, or polymyositis to name a few, it has been suggested for a long time that cGVHD is an autoimmune disease with a striking resemblance particularly to systemic sclerosis. Recently, the same group published a study in the New England Journal of Medicine1 describing the presence of stimulatory autoantibodies against the platelet-derived growth factor receptor (PDGF-R) in patients with systemic sclerosis. These antibodies activate Ha-Ras–extracellular-signal-regulated kinases 1 and 2 (ERK 1/2)–reactive oxygen species (Ha-Ras–ERK <1/2–ROS), leading to increased collagen gene expression and myofibroblast phenotype conversion of normal human primary fibroblasts. These findings suggest that stimulatory autoantibodies against the PDGF-R might play a significant role in contributing to the development of sclerodermatous lesions and development of fibrosis.

Based on the hypothesis that there might be a common underlying pathogenetic mechanism between extensive cGVHD and systemic sclerosis, Svegliati and colleagues studied a cohort of patients with extensive cGVHD for the presence of stimulatory PDGF-R antibodies. Indeed, the authors were able to identify functionally active autoantibodies against the PDGF-R in the serum of patients with extensive cGVHD. These findings have several implications: (1) The nature of the target antigens (ie, allogeneic minor antigens versus autoantigens) in cGVHD is still subject to intense investigation. The results from the Svegliati et al study provide evidence that the presence of antibodies to autoantigens is not a pure epiphenomenon in cGVHD, but rather is directly contributing to disease manifestation. (2) Similar to acute GVHD, it has been assumed that cGVHD is primarily caused by alloreactive or autoreactive (due to impaired negative selection) donor T cells. Recent evidence also supports the direct role of B cells in cGVHD. Thus, it has been shown that the presence of minor antigen-reactive antibodies correlated with the presence of cGVHD.2 Furthermore, treatment of cGVHD patients with the humanized anti-CD20 monoclonal antibody rituxan resulted in significant improvement of the disease.3 In this light, the findings of Svegliati and colleagues are direct proof that auto-antibodies may play a pivotal role in cGVHD, and underscore the notion that anti–B-cell–directed treatment strategies may be of potential benefit for the treatment of cGVHD by depleting auto- or alloreactive B cells. (3) The finding that stimulatory autoantibodies against the anti-PDGF receptor may be directly responsible for the sclerotic/fibrotic changes in cGVHD and involve tyrosine kinase–dependent/Ha-Ras–Erk-1/2–ROS signaling could provide the rationale for molecular targeted treatment of cGVHD (eg, tyrosine kinase inhibitors, farnesyltransferase inhibitors). In this context, it is of interest that the tyrosine kinase inhibitor imatinib has already been used successfully in preclinical models of dermal and pulmonary fibrosis.4

Despite the fact that these results still require confirmation and validation in a larger number of patients, the study by Svegliati and colleagues sheds new light on the pathogenesis of cGVHD. Most importantly, these findings could provide the basis for novel treatment strategies, which are desperately needed for a complex and frequently debilitating disease.

Footnotes

Conflict-of-interest disclosure: The author declares no competing financial interests. {blacksquare}

REFERENCES

  1. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354:2667–2676.[Abstract/Free Full Text]

  2. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105:2973–2978.[Abstract/Free Full Text]

  3. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108:756–762.[Abstract/Free Full Text]

  4. Distler JH, Jungel A, Huber LC, et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56:311–322.[CrossRef][Medline] [Order article via Infotrieve]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease
Silvia Svegliati, Attilio Olivieri, Nadia Campelli, Michele Luchetti, Antonella Poloni, Silvia Trappolini, Gianluca Moroncini, Andrea Bacigalupo, Pietro Leoni, Enrico V. Avvedimento, and Armando Gabrielli
Blood 2007 110: 237-241. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Arch DermatolHome page
J. A. Moreno-Romero, F. Fernandez-Aviles, E. Carreras, M. Rovira, C. Martinez, and J. M. Mascaro Jr
Imatinib as a Potential Treatment for Sclerodermatous Chronic Graft-vs-Host Disease
Arch Dermatol, September 1, 2008; 144(9): 1106 - 1109.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mapara, M. Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mapara, M. Y.
Related Collections
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020